TriangleRhDNase I (NCT07361224)
RhDNase I trial for Large B-Cell Lymphoma (LBCL) (NCT07361224). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
When large B-cell lymphoma keeps growing right up to the day CAR T therapy begins, most patients relapse within a year.
The idea: clear the debris that shields the tumor, so the CAR T cells can reach it.
Neutrophils can throw out sticky webs of DNA called NETs. In lymphoma, those webs feed tumor growth, track with worse outcomes, and may block T cells. CLS-015 is a recombinant DNase, an enzyme that digests them, given by vein five times over the two weeks after a standard CD19 CAR T infusion.
A small first safety study at Sourasky Medical Center in Tel Aviv, for patients still progressing at lymphodepletion. Ron Ram leads it. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.